By Kathryn Calkins
Staff Writer

Although much progress in drug discovery is due to cooperation between academia and industry, very close collaborations may result in toe-stomping, particularly when academic and industrial goals come to cross purposes. A good example is the tight binding of Human Genome Sciences Inc. with The Institute for Genomic Research (TIGR) under a 10-year agreement that came to an end last week.